Ngenla

Ngenla is an injection of long-acting growth hormone, administered once a week, for children 3 years and older with growth hormone deficiency. It helps support normal growth using a prefilled pen system.

Molecule Details :

  • Molecule Name :

    Somatrogon-Ghla
  • Innovator :

    OPKO/PFIZER
  • Approval Date :

    27-Jun-23
  • Data Exclusivity Expiry :

    27-Jun-27
  • Market Exclusivity Expiry :

    27-Jun-35
  • Dosage Form :

    Prefilled Injection
  • Strength :

    24mg and 60mg
  • Therapeutic Category :

    Hormonal Therapy
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    110
  • 2026 :

    196
  • 2027 :

    255
  • 2028 :

    331
  • 2029 :

    399
  • 2030 :

    457
  • 2031 :

    508
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?